Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end‐points in clinical trials
Dennis M. Donovan(University of Washington), Elizabeth A. Wells(University of Washington), John A. Hamilton(The Royal Melbourne Hospital), Jeffrey Selzer, G. Alan Marlatt(Fundación Juan March), Paul Wakim(National Institute on Drug Abuse), Kenzie L. Preston(National Institute on Drug Abuse), John G. Gardin(VA Roseburg Healthcare System), George E. Bigelow(Johns Hopkins University), Gregory S. Brigham(University of Cincinnati), Kathleen M. Carroll(Yale University), Allan Cohen(California Consortium of Addiction Programs and Professionals), John R. Hughes(University of Vermont), Marilyn A. Huestis(Smithsonian Institution), Robert Lindblad(Emmes (United States)), Eugene Somoza(University of Cincinnati)
Cited by 205
Related Papers
Human Cannabinoid Pharmacokinetics
|Chemistry & Biodiversity|2007|1.1k
Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
|Drug and Alcohol Dependence|2014|697
Neuropsychological Performance in Long-term Cannabis Users
|Archives of General Psychiatry|2001|656
Cannabis Effects on Driving Skills
|Clinical Chemistry|2012|613
Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and biofluid
|Journal of the American Society for Mass Spectrometry|2003|599